ProCE Banner Activity

First-line Management of Advanced RCC With IMDC Intermediate-/Poor-Risk Disease

Slideset

Download this slideset from Martin H. Voss, MD, to learn more about selecting optimal first-line therapy for intermediate-risk/poor-risk patients with advanced RCC.

Released: February 13, 2020

Expiration: February 11, 2021

Share

Faculty

Martin H. Voss

Martin H. Voss, MD

Attending Physician
Division of GU Medical Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
Assistant Professor

Weill Cornell Medical College
New York, New York

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from
Eisai
Pfizer and EMD Serono

Supported by a medical education grant from
Exelixis, Inc.
Supported by an independent educational grant from

Merck Oncology

Partners

Clinical Care Options, LLC

ProCE Banner

Faculty Disclosure

Primary Author

Martin H. Voss, MD

Attending Physician
Division of GU Medical Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
Assistant Professor

Weill Cornell Medical College
New York, New York